This content is from: Culture These Are the Allocator Finalists for the 2023 Hedge Fund Industry Awards Managers are now invited to vote for the winners, who will be honored at a gala dinner in May. By Alicia McElhaney March 14, 2023
This content is from: Portfolio A Jim Simons Market Mystery — Solved? A secretive investment fund backed by the legendary quant displays a penchant for biotech stocks. There’s a good reason for that. By Richard Teitelbaum February 07, 2023
This content is from: Premium Casdin Leads a Biopharma Surge Several funds that lost large amounts last year rebounded nicely in the first month of 2023. By Stephen Taub February 21, 2023
This content is from: Premium Biopharma Funds Are Still Embracing VC The number of deals is down from last year, but most firms have still been fairly active in the private markets. By Stephen Taub December 21, 2022
This content is from: Premium The Prognosis Brightens for Biopharma Funds Soleus continues to lead the recovery in what had been one of the year’s most beaten-down sectors. By Stephen Taub December 14, 2022
This content is from: Portfolio Investing in a Cure for Cancer The recently launched Loncar Cancer Immunotherapy ETF provides investors with a vehicle to bet on promising new immunotherapy treatments for cancer. By Kaitlin Ugolik June 07, 2016
